Sonja Heinzelmann1, Daniel Böhringer2, Philipp Eberwein2, Thabo Lapp2, Thomas Reinhard2, Philip Maier2. 1. Eye Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Killianstr. 5, D-79106, Freiburg im Breisgau, Germany. sonja.heinzelmann@uniklinik-freiburg.de. 2. Eye Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Killianstr. 5, D-79106, Freiburg im Breisgau, Germany.
Abstract
PURPOSE: Descemet membrane endothelial keratoplasty (DMEK) is superior to penetrating keratoplasty (PK) in terms of visual rehabilitation, intraoperative safety and risk of rejection. Therefore, it seems reasonable to perform DMEK in eyes with endothelial failure following PK. We herein report our first clinical results. METHODS: Nineteen eyes with endothelial graft failure following PK were treated with DMEK. The majority of these eyes (12) had limited visual potential. The major indication for DMEK was pain relief in patients with bullous keratopathy. Visual acuity (VA), central corneal thickness (CCT), rate of graft dislocations, graft survival, graft rejections and other complications were extracted from the medical records. RESULTS: Although comorbidities limiting VA were present in 12 of the 19 eyes, VA increased from 0.05 to 0.1 (median) in 16 eyes. CCT decreased substantially (range 63-363 μm). Rebubbling was necessary in five eyes with incomplete graft adherence. There were two immunologic graft reactions and three graft failures. No major complications like endophthalmitis or expulsive bleeding occurred. CONCLUSIONS: DMEK is feasible to treat endothelial graft failure following PK. This is even true for eyes with limited visual potential.
PURPOSE: Descemet membrane endothelial keratoplasty (DMEK) is superior to penetrating keratoplasty (PK) in terms of visual rehabilitation, intraoperative safety and risk of rejection. Therefore, it seems reasonable to perform DMEK in eyes with endothelial failure following PK. We herein report our first clinical results. METHODS: Nineteen eyes with endothelial graft failure following PK were treated with DMEK. The majority of these eyes (12) had limited visual potential. The major indication for DMEK was pain relief in patients with bullous keratopathy. Visual acuity (VA), central corneal thickness (CCT), rate of graft dislocations, graft survival, graft rejections and other complications were extracted from the medical records. RESULTS: Although comorbidities limiting VA were present in 12 of the 19 eyes, VA increased from 0.05 to 0.1 (median) in 16 eyes. CCT decreased substantially (range 63-363 μm). Rebubbling was necessary in five eyes with incomplete graft adherence. There were two immunologic graft reactions and three graft failures. No major complications like endophthalmitis or expulsive bleeding occurred. CONCLUSIONS: DMEK is feasible to treat endothelial graft failure following PK. This is even true for eyes with limited visual potential.
Authors: Daniel Böhringer; Stefan Böhringer; Katharina Poxleitner; Florian Birnbaum; Johannes Schwartzkopff; Philip Maier; Rainer Sundmacher; Thomas Reinhard Journal: Cornea Date: 2010-10 Impact factor: 2.651
Authors: Friedrich E Kruse; Kathrin Laaser; Claus Cursiefen; Ludwig M Heindl; Ursula Schlötzer-Schrehardt; Stephan Riss; Björn O Bachmann Journal: Cornea Date: 2011-05 Impact factor: 2.651
Authors: Moritz C Daniel; Lisa Atzrodt; Felicitas Bucher; Katrin Wacker; Stefan Böhringer; Thomas Reinhard; Daniel Böhringer Journal: Sci Rep Date: 2019-03-18 Impact factor: 4.379
Authors: F A Steindor; J Menzel-Severing; M Borrelli; S Schrader; G Geerling Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-04-05 Impact factor: 3.535